A scientific hub by the name Seattle Genetics is hitting high in the biotechnology industry. Following the current rise in the prevalence of cancer cases, they have been able to come up with Adcetris drug. This is a drug directed to the cure lymphomas. Due to the efforts of this company they have been lucky to host the USA’s Vice President Joe Biden and also the firm is identified as the heart for cancer research studies. The report says that more is yet to be unveiled since research is also working on other twelve drugs that will be used in the cure of several other types of cancer. Adcetris has been concentrated on the cure of myeloid leukemia cases and from its sales the organization has been able to gain about $226 million from the distributions in both USA and Canada. It has both societal and economic influence as it seeks to add more workers to the current eight hundred.
The CEO of the organization Clay Siegall is confident of major breakthroughs as seen from the success of their clinical trials. The drugs are being widely supplied, and the current stocks show an increase in the indexes showing for America, Middle East, and Africa. The CEO’s humane feeling for the care for patients is seen as his driving force to building the scientific laboratory. Through Siegall’s help, great treaties have been signed and developed technologies put in place to propel the science work.
Siegall is not just a mere business man but a professional scientist with a Bachelor degree in Zoology and Ph.D. in Genetics. Practicing his work has given a lot experience and he has also led several boards of directors namely; Ultragenyx, Mirna and Alder Biopharmaceuticals. The experience he acquired from the management of these bodies has enabled him to run his own Seattle Genetics for the last eighteen years. Hailed is his name for great awards, Entrepreneur of the Year in 2012 and Alumnus of the Year for Computer Math and Natural Sciences. Thanks to his efforts.